Analysis results revealed racial and sex disparities among patients with hypertrophic cardiomyopathy who receive implantable cardioverter-defibrillator (ICD) devices. Among patients hospitalized with ...

Chicago, IL - Only one guideline-defined risk factor for sudden cardiac death (SCD) can be enough to consider patients with hypertrophic cardiomyopathy (HCM) for a primary-prevention implantable ...

High-risk patients with hypertrophic cardiomyopathy would not have been protected from sudden death through the recommendation of an implantable cardioverter defibrillator using the European Society ...

Researchers at Tufts Medical Center report reassuring accuracy predicting which patients with a common genetic heart disease are at the most risk of sudden death and thus most need an implanted device ...

Background Risk stratification for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (HCM) remains challenging.

"Appropriately selected patients with NICM have the potential to benefit from primary prevention ICD therapy…Besides consideration of ICD placement, attention to guideline-directed medical therapy and ...

Hypertrophic cardiomyopathy (HCM) is often seen in patients as an autosomal dominant genetic heart disease with a variable clinical course. It is characterized by left ventricular hypertrophy, and ...

Background: The use of health administrative data in health services research is facilitated by standardized classification systems, such as the International Classification of Diseases (ICD). Canada, ...

Misinformation and misunderstandings surround ICD-10 as the go-live date nears. One result is that too many providers have yet to conduct testing. They should take advantage of CMS's grace period, ...

(MENAFN- Market Press Release) June 5, 2025 4:21 am - The 7 major hypertrophic cardiomyopathy markets reached a value of US$ 312.5 Million in 2023. Looking forward, IMARC Group expects the 7MM to ...